Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00667342 · OUTCOME

3-Year Event Free Survival

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma · Source last updated 2023-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Probability
Interval / dispersion
95% Confidence Interval
Time frame
After all patients have completed therapy, up to 4 years after last patient is enrolled

What was measured

To study the effect of adding bevacizumab to chemotherapy comprised of cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) on the event-free survival (EFS) in patients with localized resectable osteosarcoma. The Kaplan-Meier (K-M) method was used to estimate survival rate.

Groups in this outcome

A: Localized Resectable Disease

OS2008 Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease31

Reported measurements

Source class 1
Values in Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.575Not reported0.4020.747Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.402
        upper Limit
        0.747
        value
        0.575
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
To study the effect of adding bevacizumab to chemotherapy comprised of cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) on the event-free survival (EFS) in patients with localized resectable osteosarcoma. The Kaplan-Meier (K-M) method was used to estimate survival rate.
dispersion Type
95% Confidence Interval
groups
  1. description
    OS2008 Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.
    id
    OG000
    title
    A: Localized Resectable Disease
param Type
NUMBER
reporting Status
POSTED
time Frame
After all patients have completed therapy, up to 4 years after last patient is enrolled
title
3-Year Event Free Survival
type
PRIMARY
unit Of Measure
Probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice